Medexus Announces Conference Participation for April 2021

Medexus Pharmaceuticals Inc. (the “

Company

” or 

“Medexus

”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731), today announced that Ken d’Entremont, CEO, and Roland Boivin, CFO, will be participating in the Bloom Burton & Co. Healthcare Investor Conference as well as the Stifel 2021 Canada Cross Sector Insight Conference in the month of April.

Bloom Burton & Co. Healthcare Investor Conference

Date: Tuesday, April 20, 2021Time: 11a.m. ETRegister for the virtual conference: click here

The Bloom Burton & Co. Healthcare Investor Conference brings together U.S., Canadian and international investors who are interested in the latest developments in the Canadian healthcare sector. Attendees will have an opportunity to obtain corporate updates from the premier Canadian publicly traded and private companies through presentations and private meetings.

Stifel 2021 Canada Cross Sector Insight Conference

Medexus will also be participating in several one-on-one investor meetings on Wednesday, April 21, 2021 at the Stifel 2021 Canada Cross Sector Insight Conference. Investors should contact their Stifel representatives for more details.

About Medexus Pharmaceuticals Inc.

Medexus is a leader in innovative rare disease treatment solutions with a strong North American commercial platform. From a foundation of proven best in class products we are building a highly differentiated company with a portfolio of innovative and high value orphan and rare disease products that will underpin our growth for the next decade. The Company’s vision is to provide the best healthcare products to healthcare professionals and patients, through our core values of Quality, Innovation, Customer Service and Teamwork. Medexus Pharmaceuticals is focused on the therapeutic areas of auto-immune disease, hematology, and allergy. The Company’s leading products are: Rasuvo™ and Metoject®, a unique formulation of methotrexate (auto-pen and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY®, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B – a hereditary bleeding disorder characterized by a deficiency of clotting factor IX in the blood, which is necessary to control bleeding; and Rupall®, an innovative prescription allergy medication with a unique mode of action.

For more information, please contact:

Ken d’Entremont, Chief Executive OfficerMedexus Pharmaceuticals Inc.Tel.: [phone]E-mail: [e-mail]

Roland Boivin, Chief Financial OfficerMedexus Pharmaceuticals Inc.Tel.: [phone]E-mail: [e-mail]

Investor Relations (U.S.):Crescendo Communications, LLCTel: [phone]E-mail: [e-mail]

Investor Relations (Canada):Tina ByersAdelaide CapitalTel: 905-330-3275E-mail: [e-mail] the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.